Comparing outcomes of two surgical procedures for shoulder instability
Return to Sport and Functional Performance Following Surgical Intervention for Anterior Glenohumeral Instability (AGHI)
This study is testing which of two shoulder surgeries helps people aged 18 to 50 with repeated shoulder dislocations feel better and get back to sports more effectively.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 72 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Panam Clinic Academic / other |
| Locations | 1 site (Winnipeg, Manitoba) |
| Trial ID | NCT05151965 on ClinicalTrials.gov |
What this trial studies
This prospective cohort study aims to compare the patient-reported, clinical, and functional outcomes of two surgical interventions—Bankart repair with Remplissage and Latarjet coracoid transfer—for anterior glenohumeral instability. Patients aged 18 to 50 who have experienced multiple shoulder dislocations will be followed for up to 24 months post-surgery. The study also focuses on the rates of return to sport and performance in athletic patients undergoing these procedures.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18 to 50 who have experienced two or more anterior shoulder dislocations and have specific imaging findings indicating less than 25% glenoid bone loss.
Not a fit: Patients with significant glenoid defects, previous shoulder surgeries, or other serious shoulder conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify which surgical approach leads to better recovery and return to sports for patients with shoulder instability.
How similar studies have performed: Other studies have explored similar surgical interventions for shoulder instability, showing varying degrees of success, but this specific comparison is less commonly addressed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 - 50 years * Documented reduction of anterior shoulder dislocation * Patient has suffered two or more dislocations of the study shoulder * Physical examination elicits unwanted glenohumeral translation with reproduction of symptoms * Glenoid bone loss defined on CT (or MRI) using standardized and reproducible best-fit circle techniques \< 25% * Able to benefit from surgical intervention Exclusion Criteria: * Glenoid defect in the affected shoulder ≥ 25% of the AP diameter of the glenoid * Previous surgery on affected shoulder (ANY type of shoulder surgery) * Significant shoulder comorbidities including osteoarthritis or other shoulder conditions including multi-directional instability * Participant is involved in litigation or a workplace insurance claim (i.e., WCB). * Confirmed connective tissue disorder (i.e., Ehlers-Danlos, Marfans) * Beighton hypermobility score of \>6 * Active joint or systemic infection, significant muscle paralysis, rotator cuff tear arthropathy, Charcot's arthropathy, significant medical comorbidity that could alter the effectiveness of the surgical intervention (e.g., Cervical radiculopathy, polymyalgia rheumatica) * Major medical illness (life expectancy less than 1 year) or unacceptably high operative risk * Epilepsy * Any condition that precludes informed consent (i.e. psychiatric illness) * Unable to speak or read English/French * Unable or unwilling to be followed for 2 years or complete functional testing
Where this trial is running
Winnipeg, Manitoba
- Pan Am Clinic — Winnipeg, Manitoba, Canada (Recruiting)
Study contacts
- Principal investigator: Dan Ogborn, PhD — Pan Am Clinic
- Study coordinator: Dan Ogborn, PhD
- Email: dogborn@panamclinic.com
- Phone: 204-927-2829
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.